RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00034925.xml
PDF herunterladen
Hamostaseologie 1986; 06(02): 93-98
DOI: 10.1055/s-0038-1655143
DOI: 10.1055/s-0038-1655143
Originalarbeiten
Der plättchenaktivierende Faktor (PAF)
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
25. Juni 2018 (online)
-
Literatur
- 1 Benveniste J, Henson P M, Cochrane C G. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils, and a platelet activating factor. J exp Med 1972; 136: 1356-77.
- 2 Benveniste J, LeCouedic J P, Kamoun P. Aggregation of human platelets by plateletactivating factor. Lancet 1975; I: 344-5.
- 3 Benveniste J, LeCouedic J P, Polonsky J, Tence M. Structural analysis of purified platelet-activating factor by lipases. Nature (Lond) 1977; 269: 170-1.
- 4 Benveniste J, Roubin R, Chignard M, Jouvin-Marche E, LeCouedic J P. Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from 3 cell types. Agents and Actions 1982; 12: 711-3.
- 5 Benveniste J, Tence M, Varenne P, Bidault J, Boullet C, Polonsky J. Semi-synthèse et structure proposée du facteur activant le plaquettes (PAF): PAF-acéther, un alkyl éther analogue de la lysophosphatidylcholine. C R Acad Sci D (Paris) 1979; 289: 1037-40.
- 6 Benveniste J, Vargaftig B B. Platelet-activating factor: An ether lipid with biological activity. In: Ether Lipids: Biochemical and Biomedical Aspects. Mangold H K, Paldauf F. (Eds.). Academic Press; London, New York: 1983: 355-75.
- 7 Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J. Acute circulatory collapse caused by PAF in dogs. Eur J Pharmacol 1983; 86: 403-13.
- 8 Bonnet J, Loiseau A M, Orvoen M, Bessin P. PAF involvement in acute inflammatory and pain processes. Agents and Actions 1981; 11: 559-62.
- 9 Camussi G, Aglietta M, Coda R, Bussolino F, Piacihollo W, Tetta C. Release of platelet activating factor (PAF) and histamine. Immunology 1984; 42: 191-9.
- 10 Cargill D I, Cohen D S, VanValen R G, Klimek J J, Levin R P. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). Thrombos Haemostas 1983; 49: 204-7.
- 11 Cazenave J P, Benveniste J, Mustard J. Aggregation of rabbit platelets by plateletactivating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. J Lab Invest 1979; 41: 275-85.
- 12 Chignard M, LeCouedic J P, Vargaftig B B, Benveniste J. Platelet-activating factor (PAF-acether) secretion from platelets : Effects of aggregating agents. Br J Haemat 1980; 46: 455-64.
- 13 Demopoulos C A, Pinckard R N, Hanahan D J. Platelet-activating factor. Evidence for l-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J biol Chem 1979; 254: 9355-8.
- 14 d’Lumierès S, Russo-Marie F, Vargaftig B B. PAF-acether induces the release of prostacyclin in cultured human endothelial cells. Thrombos Haemostas 1985; 54: 174 (Abstr).
- 15 Findlay S R, Lichtenstein L M, Hanahan D J, Pinckard R N. The contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol 1981; 241: 130-4.
- 16 Godfroid J J, Heymans F, Michel E, Redeuil H C, Steiner E, Benveniste J. Platelet activating factor (PAF-acether): total synthesis of l-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphorylcholine. FEBS Lett 1980; 116: 161-4.
- 17 Hanahan D J, Weintraub S T. Plateletactivating factor isolation, identification, and assay. Meth biochem Analys 1985; 31: 195-219.
- 18 Henson P M. Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J exp Med 1970; 131: 287-306.
- 19 Heymans F, Michel E, Borrel M C, Wichrowski B, Godfroid J J, Convert O, Coeffier E, Tence M, Benveniste J. New total synthesis and high resolution 1H NMR spectrum of platelet activating factor, its enantiomer and racemic mixtures. Biochim biophys Acta 1981; 666: 230-7.
- 20 Jouvin-Marche E, Cerrina J, Coeffiër E, Duroux P, Benveniste J. Effect of the Ca2+antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and â-glucuronidase from human neutrophils. Eur J Pharmacol 1983; 89: 19-26.
- 21 Klöcking H-P, Markwardt F, Hoffmann A. Release of tissue-type plasminogen activator by platelet-activating factor. Thrombos Res 1985; 38: 413-6.
- 22 Kravis T C, Henson P M. IgE-induced release of platelet-activating factor from rabbit lung. J Immunol 1975; 115: 1677-81.
- 23 Lefer A M, Müller H F, Smith J B. Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol 1984; 83: 125-30.
- 24 Lewis J C, O’Flaherty J T, McCall C M, Wykle R L. Endothelial alterations during the platelet activating factor (PAF) respiratory distress syndrome. Thrombos Haemostas 1981; 46: 293 (Abstr).
- 25 McManus L M, Hanahan D J, Pinckard R N. Human platelet stimulation by acetylglyceryl ether phosphoryl choline. J clin Invest 1981; 67: 903-6.
- 26 Nunez D, Chignard M, Novel X, Braquet P, Benveniste J. BN 52021 isolated from Ginkgo biloba, a specific inhibitor of the PAFacether-induced platelet activation. Comparative studies with kadsurenone. Thrombos Haemostas 1985; 54: 135 (Abstr).
- 27 O’Donnell M, Henson P M, Fiedel B A. Activation of human platelets by plateletactivating factor (PAF) derived from sensitized rabbit basophils. Immunology 1979; 35: 953-8.
- 28 Page C P, Archer C B, Paul W, Morley J. Paf-acether: a mediator of inflammation and asthma. Trends Pharmacol Sci 1984; 05: 239-41.
- 29 Pinckard R N, Halonen M, Palmer J D, Butler C, Shaw J O, Henson P M. Intravascular aggregation and pulmonary sequestration of platelets during IgE-induced systemic anaphylaxis in the rabbit. Abrogation of lethal anaphylactic shock by platelet depletion. J Immunol 1977; 119: 2185-93.
- 30 Pinckard R N, McManus L M, Hanahan D J. Chemistry and biology of acetyl glyceryl ether phosphoryl-choline (platelet-activating factor). In: Advances in Inflammation Research. Vol 4. Weissmann G. (Ed). Raven Press; New York: 1982: 147-80.
- 31 Polonsky J, Tence M, Varenne P, Das B C, Lunel J, Benveniste J. Release of 1-O-alkylglyceryl-3-phosphorylcholines, O-deacetyl platelet-activating factor (lyso-PAF-acether) from leukocytes: chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci USA 1981; 77: 7019-23.
- 32 Prop G, Doppelfeld I S, Betzing H, Graf E. Cardiovascular effects of platelet-activating factor (PAF) in rats and dogs. NaunynSchmiedeberg’s Arch Pharmacol 1981; 316 Suppl, Abstr 165.
- 33 Siraganian R P, Osier A G. Destruction of rabbit platelets in the allergic response of sensitized leukocytes. Demonstration of a fluid phase intermediate. J Immunol 1971; 106: 1244-51.
- 34 Stimler N P, O’Flaherty J T. Spasmogenic properties of platelet-activating factor. Evidence for a direct mechanism in the contractile response of pulmonary tissue. Am J Path 1983; 113: 75-84.
- 35 Tanaka S, Kosuya Y, Masuda Y, Shigenobu K. Studies on the hypotensive effect of platelet activating factor (PAF, l-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits and dogs. J Pharm Dyn 1983; 06: 866-73.
- 36 Vargaftig B B. Thromboxanes: so what. Trends Pharmacol Sci 1980; 01: 415-6.
- 37 Vargaftig B B, Chignard M, Benveniste J, Lefort J, Wal F. Background and present status of research on platelet-activating factor (PAF-acether). Ann NY Acad Sci 1981; 370: 119-37.
- 38 Vargaftig B B, Chignard M, Mencia-Huerta J M, Arnoux B, Benveniste J. Pharmacology of arachidonate metabolites and of platelet-activating factor (PAF-acether). In: Platelets in Biology and Pathology. Vol 2 Gordon J L. (Ed). Elsevier; New York: 1981: 373-406.
- 39 Vargaftig B B, Fouque F, Benveniste J, Odiot J. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. Thrombos Res 1982; 28: 557-73.
- 40 Vargaftig B B, Lefort J, Chignard M, Benveniste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1981; 65: 185-92.